CelluCore - T

Dual Incretin Receptor Agonist (GLP-1 + GIP)

Mechanism of Action:
CelluCore-T activates both GLP-1 and GIP receptors, mimicking the incretin response to amplify insulin secretion, suppress glucagon release, delay gastric emptying, and increase satiety. The dual-receptor mechanism enhances efficacy in reducing body weight and improving glycemic control compared to single-pathway therapies.

Clinical Applications:

• Type 2 Diabetes with elevated A1c

• Moderate to severe obesity (BMI ≥30)

• Patients who have plateaued on Semaglutide

• Individuals requiring stronger appetite suppression and insulin modulation

Administration:

• Subcutaneous injection once weekly

• Standard titration protocol over 8–12 weeks to minimize GI side effects

• Can be combined with lifestyle coaching, nutraceuticals, or functional labs

Expected Benefits:

• Enhanced insulin sensitivity and glycemic regulation

• Substantial reductions in body weight and waist circumference

• Significant appetite suppression and reduced food noise

• Sustained effects on metabolic inflammation and lipid profiles

Recommended Testing Before Initiation

To ensure the safety and suitability of CelluCore - T therapy, the following evaluations are recommended:

Baseline Labs:

• Comprehensive Metabolic Panel (CMP)

• HbA1c and fasting insulin

• Lipid Panel

• Thyroid Panel (TSH, free T3, free T4)

• CBC (with hematocrit and WBC count)

• C-reactive protein (CRP) or other inflammatory markers

• Optional: Fasting leptin, ghrelin, or adiponectin (in advanced cases)

Medical Evaluation:

• Complete medical and family history

• Weight/BMI and body composition analysis

• Gastrointestinal function (assess for gastroparesis or motility issues)

• Medication history, especially concurrent insulin or oral glucose-lowering agents

• Screening for eating disorders or significant psychological factors

Contraindications

Do not prescribe GLP-1/GIP/glucagon-based therapies to patients with the following:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• History of pancreatitis

• Uncontrolled gallbladder disease or hepatic dysfunction

• Severe gastrointestinal disorders (e.g., gastroparesis)

• Pregnancy or breastfeeding (Category C)

• Concurrent use of insulin without careful oversight

• Known hypersensitivity to any active component or excipients

Ongoing Monitoring Recommendations

Once therapy is initiated, providers should:

• Monitor weight, labs, and metabolic markers every 8–12 weeks

• Adjust dosing based on tolerance and clinical outcomes

• Educate patients on lifestyle optimization (nutrition, hydration, movement)

• Watch for side effects such as nausea, constipation, fatigue, or dizziness

• Be alert to signs of gallbladder dysfunction, pancreatitis, or thyroid issues

Medical Disclaimer

Cellular Health MD provides compounded peptide therapies for clinical use by licensed medical professionals only. These compounds:

• Are not FDA-approved for weight loss but are supported by ongoing clinical trials and research

• Are intended for research-based or off-label use under physician discretion

• Must be prescribed, monitored, and administered by a licensed healthcare provider

• Require proper documentation, informed consent, and medical supervision

These therapies are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary depending on genetics, health history, and compliance.